Zaeske Adam H. 4

What Happened Adam H. Zaeske, Chief Commercial Officer of Harmony Biosciences (HRMY), received compensatory equity awards on January 22, 2026: a stock option award covering 56,900 underlying shares and restricted stock units (RSUs) covering 16,200 shares, for a total of 73,100 share-equivalents. Both awards were reported as grants (derivative transactions) at $0.00 per share (i.e., compensatory awards rather than open-market purchases).

Key Details

• Transaction date: January 22, 2026; filing date: January 26, 2026 (timely filed within required Form 4 window).
• Award types and amounts: 56,900-share option award; 16,200 RSUs; total 73,100 share-equivalents.
• Reported price: $0.00 (compensatory grants).
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Footnote F1 (options): 25% of the option shares vest on January 22, 2027, with the remainder vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to continued service.
• Footnote F2 (RSUs): RSUs vest in four equal annual installments beginning January 22, 2027; each RSU converts to one share and has no expiration date.

Context These were company compensation awards (not open-market purchases or sales). The option and RSU grants are typical long-term incentive awards for executives and vest over multiple years contingent on continued service; they do not represent an immediate cash transaction or a sale of stock.